Blood Screening Market
SHARE
PUBLISHED: 2022 ID: SMRC21578
SHARE

Blood Screening Market Forecasts to 2028 – Global Analysis By Product & Services (Software and Services, Instruments), Technology (Western Blot Assay, Rapid Tests, Next-generation Sequencing (NGS)), Application (Diabetes Blood Testing, Cardiovascular Disease Blood Testing) and By Geography

4.8 (21 reviews)
4.8 (21 reviews)
Published: 2022 ID: SMRC21578

This report covers the impact of COVID-19 on this global market
Loading...

According to Stratistics MRC, the Global Blood Screening Market is accounted for $2.59 billion in 2021 and is expected to reach $5.18 billion by 2028 growing at a CAGR of 10.4% during the forecast period. Blood Screening tests are the foundation of a successful healthcare system, providing critical information those healthcare providers and patients need to make the right medical decisions. Blood screening often provides objective, quantitative measurements that inform every stage of care—prevention, detection, diagnosis, treatment, and successful management of health conditions.

Market Dynamics:

Driver:

Growing number of blood donations


The increasing consciousness concerning blood safety from infectious diseases through several programs is leading to high demand for blood screening tests worldwide. Increasing cases of accidents and the prevalence of chronic diseases like cancer are creating a huge demand for blood for the treatment of the patient population. It was also validated by numerous studies that a single victim of a car accident can require up to 100 units of blood and also while receiving a chemotherapy treatment some the cancer patients require blood transfusion. Hence, a large patient pool of cancer coupled with an increase in accidental cases are generating a high demand for blood for their treatment and subsequently increasing the acceptance of blood screening tests during the forecast period.

Restraint:

High Cost


One of the major factors restraining the market growth is the lack of expenditure on healthcare infrastructure in developing countries for blood screening procedures. The high cost related to the test instruments and stringent regulatory policies is some of the factors expected to restraint the growth of the market.

Opportunity:

Introduction of Automated Molecular Platforms


Growing automation is predictable to eliminate human error during the transfusion screening process. Mostly, these screening tests influence a majority of medical decisions made in blood banks and hospitals.  The introduction of such automated molecular platforms by key players has subsequently resulted in its increasing adoption in blood donation centers. This is predictable to create ample opportunity for market growth.

Threat:

Substitute technologies


Digital immunoassays are a one-step solution for single-molecule detection without requiring washing steps based on ELISA using an array of femtoliter-sized wells. This tests have seen significant interest owing to the urgent and ever-increasing demand for serological COVID-19 antibody tests that are inexpensive, rapid, simple, highly sensitive, quantitative, and minimally invasive. Therefore, a single-step, wash-free immunoassay for rapid and highly sensitive quantitative analysis of human serological IgG against SARS-CoV-2 has been developed, which requires only a single droplet of serum.

Blood banks segment is expected to be the largest during the forecast period

The blood banks segment commanded the largest share of the market. Laboratory screening of donated blood and blood products for infectious diseases is a key safety measure to protect patients and prevent the spread of serious infectious diseases. Factors such as rising blood donations and transfusion-related screenings, increasing awareness about transfusion-transmitted infections, and the rising occurrence of infectious diseases are driving the growth of this segment.

The reagents & kits segment is expected to have the highest CAGR during the forecast period

The reagents & kits segment is expected to have the highest CAGR, as reagents being a recurrent expense are widely used for immunoassays and molecular tests. Reasons such as rising blood donations and transfusion-related screenings, the increasing prevalence of infectious diseases and there has been an increase in serological testing, which has contributed to the growth of this segment.

Region with highest share:

The Asia Pacific is projected to hold the highest market share, owing to access to optimal treatment facilities and increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure. Countries in the Asia pacific provinces, such as China and India, are the hotspots for investment opportunities owing to treatment and research activities, a growing number of partnerships and healthcare modernization, growing rate of diagnosis, and quality improvisations are some of the factors motivating the market growth in the Asia Pacific region.

Region with highest CAGR:

North America is projected to have the highest CAGR, North America’s largest share is primarily accredited to the growing blood transfusion-related screenings, growing prevalence of infectious diseases, rising geriatric population, need for early disease diagnosis and monitoring, increasing healthcare expenditure, and the growing adoption of advanced blood screening technologies in the province.

Key players in the market:

Some of the key players profiled in the Blood Screening Market include Abbott Laboratories, Alere Inc., Apex Biotechnology Corp, Beckman Coulter (A Subsidiary of Danaher Corporation), Becton, Dickinson and Company, Biomérieux, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche, Grifols, Hemosense Inc, Luminex Corp, Nova Biomedical Corp, Ortho Clinical Diagnostics, Inc, Roche Diagnostics, Siemens Healthineers (A Subsidiary of Siemens AG), Thermo Fisher Scientific, Inc, Trinity Biotech.

Key developments:

In October 2020: Siemens Healthineers announced shipping worldwide its laboratory-based total antibody test1 to detect the presence of SARS-CoV-2 IgM and IgG antibodies in the blood. The complete antibody test permits the identification of patients who have developed an adaptive immune response.

In February 2020: BD (US) acquired NAT Diagnostics (US), this acquisition strengthened an early-stage company developing a molecular diagnostic platform for POC testing.

In September 2021: Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Product & Services Covered: 
• Software and Services 
• Instruments  
• Reagents & Kits   

Technology’s Covered:
• Western Blot Assay  
• Rapid Tests  
• Next-generation Sequencing (NGS)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Nucleic Acid Test (NAT)    

Applications Covered:
• Diabetes Blood Testing 
• Cardiovascular Disease Blood Testing
• Cancer Blood Testing 
• Blood Disorder Blood Testing 
• Autoimmune Disease And Food Allergy Testing
• Pregnancy Blood Testing 
• Liver Disorder Blood Testing 
• Kidney Disorder Blood Testing 
• Home-Monitoring Blood Testing
• Fertility Blood Testing    

End Users Covered: 
• Blood Banks  
• Hospitals     

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China       
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary   
    
2 Preface   

 2.1 Abstract  
 2.2 Stake Holders  
 2.3 Research Scope  
 2.4 Research Methodology  
  2.4.1 Data Mining 
  2.4.2 Data Analysis 
  2.4.3 Data Validation 
  2.4.4 Research Approach 
 2.5 Research Sources  
  2.5.1 Primary Research Sources 
  2.5.2 Secondary Research Sources 
  2.5.3 Assumptions 
    
3 Market Trend Analysis   
 3.1 Introduction  
 3.2 Drivers  
 3.3 Restraints  
 3.4 Opportunities  
 3.5 Threats  
 3.6 Technology Analysis  
 3.7 Application Analysis  
 3.8 End User Analysis  
 3.9 Emerging Markets  
 3.10 Impact of Covid-19  
    
4 Porters Five Force Analysis   
 4.1 Bargaining power of suppliers  
 4.2 Bargaining power of buyers  
 4.3 Threat of substitutes  
 4.4 Threat of new entrants  
 4.5 Competitive rivalry  
    
5 Global Blood Screening Market, By Product & Service   
 5.1 Introduction  
 5.2 Software and Services    
 5.3 Instruments     
  5.3.1 Rental Purchase   
  5.3.2 Outright Purchase   
 5.4 Reagents & Kits     
  5.4.1 ELISA Reagents & Kits  
   5.4.1.1 Substrates 
   5.4.1.2 Sample Diluents and Wash Solutions
   5.4.1.3 Immunosorbents 
   5.4.1.4 Controls  
   5.4.1.5 Conjugates 
  5.4.2 NAT Reagents & Kits  
   5.4.2.1 Standards and Controls
   5.4.2.2 Probes and Primers 
   5.4.2.3 Labeling and Detection Reagents
   5.4.2.4 Enzymes and Polymerases
   5.4.2.5 Buffers, Nucleotides, and Solutions
    
6 Global Blood Screening Market, By Technology   
 6.1 Introduction  
 6.2 Western Blot Assay     
 6.3 Rapid Tests     
 6.4 Next-generation Sequencing (NGS)   
 6.5 Enzyme-Linked Immunosorbent Assay (ELISA)   
  6.6.1 By Platform   
   6.6.1.1 Fluorescence Immunoassay (FIA)
   6.6.1.2 Colorimetric Immunoassay (CI)
   6.6.1.3 Chemiluminescence Immunoassay (CLIA)
  6.6. By Generation    
   6.6.1 Third Generation 
   6.6.2 Second Generation 
   6.6.3 Fourth Generation & Above
   6.6.4 First Generation 
 6.6 Nucleic Acid Test (NAT)     
  6.6.1 Transcription-Mediated Amplification (TMA) 
  6.6.2 Real-Time Polymerase Chain Reaction (PCR) 
    
7 Global Blood Screening Market, By Application   
 7.1 Introduction  
 7.2 Diabetes Blood Testing    
 7.3 Cardiovascular Disease Blood Testing   
 7.4 Cancer Blood Testing    
 7.5 Blood Disorder Blood Testing    
 7.6 Autoimmune Disease And Food Allergy Testing  
 7.7 Pregnancy Blood Testing    
 7.8 Liver Disorder Blood Testing    
 7.9 Kidney Disorder Blood Testing    
 7.10 Home-Monitoring Blood Testing   
 7.11 Fertility Blood Testing    
    
8 Global Blood Screening Market, By End User   
 8.1 Introduction  
 8.2 Blood Banks     
 8.3 Hospitals     
    
9 Global Blood Screening Market, By Geography   
 9.1 Introduction  
 9.2 North America  
  9.2.1 US 
  9.2.2 Canada 
  9.2.3 Mexico 
 9.3 Europe  
  9.3.1 Germany 
  9.3.2 UK 
  9.3.3 Italy 
  9.3.4 France 
  9.3.5 Spain 
  9.3.6 Rest of Europe 
 9.4 Asia Pacific  
  9.4.1 Japan 
  9.4.2 China 
  9.4.3 India 
  9.4.4 Australia 
  9.4.5 New Zealand 
  9.4.6 South Korea 
  9.4.7 Rest of Asia Pacific 
 9.5 South America  
  9.5.1 Argentina 
  9.5.2 Brazil 
  9.5.3 Chile 
  9.5.4 Rest of South America 
 9.6 Middle East & Africa  
  9.6.1 Saudi Arabia 
  9.6.2 UAE 
  9.6.3 Qatar 
  9.6.4 South Africa 
  9.6.5 Rest of Middle East & Africa 
     
10 Key Developments   
 10.1 Agreements, Partnerships, Collaborations and Joint Ventures  
 10.2 Acquisitions & Mergers  
 10.3 New Product Launch  
 10.4 Expansions  
 10.5 Other Key Strategies  
    
11 Company Profiling   
 11.1 Abbott Laboratories     
 11.2 Alere Inc.      
 11.3 Apex Biotechnology Corp.    
 11.4 Beckman Coulter (A Subsidiary of Danaher Corporation)   
 11.5 Becton, Dickinson and Company   
 11.6 Biomérieux      
 11.7 Bio-Rad Laboratories, Inc.     
 11.8 F. Hoffmann-La Roche     
 11.9 Grifols       
 11.10 Hemosense Inc.     
 11.11 Luminex Corp.     
 11.12 Nova Biomedical Corp.    
 11.13 Ortho Clinical Diagnostics, Inc.    
 11.14 Roche Diagnostics     
 11.15 Siemens Healthineers (A Subsidiary of Siemens AG)   
 11.16 Thermo Fisher Scientific, Inc.     
 11.17 Trinity Biotech   


List of Tables    
1 Global Blood Screening Market Outlook, By Region (2020-2028) (US $MN)    
2 Global Blood Screening Market Outlook, By Product & Service (2020-2028) (US $MN)   
3 Global Blood Screening Market Outlook, By Software and Services (2020-2028) (US $MN)   
4 Global Blood Screening Market Outlook, By Instruments (2020-2028) (US $MN)   
5 Global Blood Screening Market Outlook, By Rental Purchase (2020-2028) (US $MN)   
6 Global Blood Screening Market Outlook, By Outright Purchase (2020-2028) (US $MN)   
7 Global Blood Screening Market Outlook, By Reagents & Kits (2020-2028) (US $MN)   
8 Global Blood Screening Market Outlook, By ELISA Reagents & Kits (2020-2028) (US $MN)   
9 Global Blood Screening Market Outlook, By NAT Reagents & Kits (2020-2028) (US $MN)   
10 Global Blood Screening Market Outlook, By Technology (2020-2028) (US $MN)   
11 Global Blood Screening Market Outlook, By Western Blot Assay (2020-2028) (US $MN)   
12 Global Blood Screening Market Outlook, By Rapid Tests (2020-2028) (US $MN)   
13 Global Blood Screening Market Outlook, By Next-generation Sequencing (NGS) (2020-2028) (US $MN)   
14 Global Blood Screening Market Outlook, By Enzyme-Linked Immunosorbent Assay (ELISA)  (2020-2028) (US $MN)   
15 Global Blood Screening Market Outlook, By By Platform (2020-2028) (US $MN)   
16 Global Blood Screening Market Outlook, By By Generation (2020-2028) (US $MN)   
17 Global Blood Screening Market Outlook, By Nucleic Acid Test (NAT) (2020-2028) (US $MN)   
18 Global Blood Screening Market Outlook, By Transcription-Mediated Amplification (TMA) (2020-2028) (US $MN)   
19 Global Blood Screening Market Outlook, By Real-Time Polymerase Chain Reaction (PCR) (2020-2028) (US $MN)   
20 Global Blood Screening Market Outlook, By Application (2020-2028) (US $MN)   
21 Global Blood Screening Market Outlook, By Diabetes Blood Testing (2020-2028) (US $MN)   
22 Global Blood Screening Market Outlook, By Cardiovascular Disease Blood Testing (2020-2028) (US $MN)   
23 Global Blood Screening Market Outlook, By Cancer Blood Testing (2020-2028) (US $MN)   
24 Global Blood Screening Market Outlook, By Blood Disorder Blood Testing (2020-2028) (US $MN)   
25 Global Blood Screening Market Outlook, By Autoimmune Disease And Food Allergy Testing (2020-2028) (US $MN)   
26 Global Blood Screening Market Outlook, By Pregnancy Blood Testing (2020-2028) (US $MN)   
27 Global Blood Screening Market Outlook, By Liver Disorder Blood Testing (2020-2028) (US $MN)   
28 Global Blood Screening Market Outlook, By Kidney Disorder Blood Testing (2020-2028) (US $MN)   
29 Global Blood Screening Market Outlook, By Home-Monitoring Blood Testing (2020-2028) (US $MN)   
30 Global Blood Screening Market Outlook, By Fertility Blood Testing (2020-2028) (US $MN)   
31 Global Blood Screening Market Outlook, By End User (2020-2028) (US $MN)   
32 Global Blood Screening Market Outlook, By Blood Banks (2020-2028) (US $MN)   
33 Global Blood Screening Market Outlook, By Hospitals (2020-2028) (US $MN)   
    
Note- Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.  

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials